Iotrolan
Osmovist (iotrolan) is an unknown pharmaceutical. Iotrolan was first approved as Osmovist 190 on 1989-12-07.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
19 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Coronary artery disease | D003324 | I25.1 | — | — | — | 2 | 1 | 3 | |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | — | — | — | 2 | — | 2 |
| Hypothyroidism | D007037 | EFO_0004705 | E03.9 | — | — | — | 1 | — | 1 |
| Inferior wall myocardial infarction | D056989 | EFO_1000983 | — | — | — | 1 | — | 1 | |
| Chronic renal insufficiency | D051436 | N18 | — | — | — | 1 | — | 1 | |
| Coronary angiography | D017023 | — | — | — | 1 | — | 1 | ||
| Renal insufficiency | D051437 | HP_0000083 | N19 | — | — | — | 1 | — | 1 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | — | 1 | — | 1 |
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypersensitivity | D006967 | EFO_0003785 | T78.40 | — | — | — | — | 1 | 1 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | — | — | 1 | 1 |
| Angiography | D000792 | — | — | — | — | 1 | 1 | ||
| Multidetector computed tomography | D061330 | — | — | — | — | 1 | 1 | ||
| Neuroendocrine carcinoma | D018278 | — | — | — | — | 1 | 1 | ||
| Angiocardiography | D000790 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | IOTROLAN |
| INN | iotrolan |
| Description | Iotrolan (trade name Isovist) is an iodine-containing radiocontrast agent, a substance used to improve the visibility of body structures on images obtained by X-ray techniques.
|
| Classification | Small molecule |
| Drug class | iodine-containing contrast media |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CN(C(=O)CC(=O)N(C)c1c(I)c(C(=O)NC(CO)C(O)CO)c(I)c(C(=O)NC(CO)C(O)CO)c1I)c1c(I)c(C(=O)NC(CO)C(O)CO)c(I)c(C(=O)NC(CO)C(O)CO)c1I |
Identifiers
| PDB | — |
| CAS-ID | 79770-24-4 |
| RxCUI | 51474 |
| ChEMBL ID | CHEMBL1200555 |
| ChEBI ID | — |
| PubChem CID | 3738 |
| DrugBank | DB09487 |
| UNII ID | 16FL47B687 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 122 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
7,634 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more